Enhanced Hyaluronate Compositions and Soft Tissue Fillers
Legal Citation
Summary of the Inventive Concept
Improved hyaluronate compositions and soft tissue fillers with enhanced injectability, biocompatibility, controlled release, stability, and viscoelastic properties, addressing the limitations of existing hyaluronic acid-based products.
Background and Problem Solved
The original patent disclosed methods for making modified hyaluronate compositions, but these compositions still had limitations, such as poor injectability, variable biocompatibility, and inadequate control over release and degradation rates. The new inventive concept addresses these limitations by introducing novel compositions and methods that enhance the performance and safety of hyaluronic acid-based soft tissue fillers.
Detailed Description of the Inventive Concept
The new inventive concept comprises four main aspects: 1) a method for preparing a hyaluronate composition with improved injectability by adding a lubricating agent, 2) a hyaluronate-based soft tissue filler with enhanced biocompatibility and reduced particle size, 3) a system for controlled release of hyaluronate in soft tissue using a tunable degradation rate, and 4) a method for producing a hyaluronate composition with improved stability through lyophilization. These aspects are achieved through novel combinations of crosslinking, particle size control, and delivery systems.
Novelty and Inventive Step
The new claims introduce several novel and non-obvious features, including the use of lubricating agents to enhance injectability, the reduction of particle size to minimize post-injection swelling and discomfort, the tunable degradation rate for controlled release, and the lyophilization step for improved stability. These features provide a significant improvement over the existing patent and demonstrate a clear inventive step.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include the use of different lubricating agents, varying particle sizes, and alternative delivery systems. Additionally, the tunable degradation rate could be achieved through different crosslinking agents or methods, and the lyophilization step could be replaced with other drying methods.
Potential Commercial Applications and Market
The enhanced hyaluronate compositions and soft tissue fillers have significant commercial potential in the cosmetic and pharmaceutical industries, particularly in the areas of dermal fillers, soft tissue augmentation, and tissue engineering. The improved performance and safety of these products could lead to increased market share and revenue growth.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K9/1652 |
| A | A61 | A61K8/735 |
| A | A61 | A61K9/0019 |
| A | A61 | A61K9/06 |
| A | A61 | A61K9/1658 |
| A | A61 | A61K31/167 |
| A | A61 | A61K47/42 |
| A | A61 | A61Q19/08 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Biomaterials and pharmaceutical formulations, specifically hyaluronic acid-based soft tissue fillers and drug delivery systems, requiring expertise in polymer chemistry, biotechnology, and medical device engineering
Person of Ordinary Skill (PHOSITA) Profile
A professional with advanced degree (MS/PhD) in biomaterials science, polymer chemistry, or biomedical engineering, with 3-5 years experience in developing injectable biomaterials, familiar with crosslinking techniques, particle size modification, and soft tissue delivery systems
Obviousness Rationale
A PHOSITA would recognize that the PTD's variations represent predictable engineering modifications to the source patent's hyaluronate composition, utilizing standard techniques in biomaterial design such as particle size reduction, lubricant addition, and controlled crosslinking to enhance injectable performance and tissue compatibility.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,682 |
|---|---|
| Title | Hyaluronate compositions and soft tissue fillers |
| Assignee(s) | AMC |